A Phase IIa, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-Over Study to Assess the Efficacy, Safety ,Tolerability and Pharmacokinetics of Three Oral AZD1446 Dose Regimens and Placebo During 2 Weeks of Treatment in Adult Non-Users and Users of Nicotine Containing Products.
Phase of Trial: Phase II
Latest Information Update: 01 Mar 2014
At a glance
- Drugs AZD 1446 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 08 Oct 2010 Primary endpoint 'Symptom score' has not been met.
- 08 Oct 2010 Top-line results reported in a Targacept media release.
- 08 Oct 2010 Primary endpoint 'Conners' Attention Deficit Hyperactivity Disorder Rating Scale' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History